Dopavision Appoints Mark S. Wuttke, Ph.D., as Director
– Former Novartis Ophthalmology Program Manager Significantly Strengthens Dopavision’s Management Capabilities
– The company recently launched a clinical trial of a new digital treatment for childhood myopia
Berlin, Germany, May 25, 2022 — Dopavision, a pioneering company in the development of digital therapies, today announced that Mark S. Wuttke, Ph.D., has been named the company’s Chief Executive Officer. He succeeds Dopavision co-founder and former CEO Stefan Zundel, who will remain on Dopavision’s advisory board and continue to advise the company.
Mark Wuttke brings more than two decades of healthcare industry expertise, including extensive experience in the development and commercialization of ophthalmic products at Novartis, a global leader in eye health. He also has a strong background in corporate strategy and branding. Prior to joining Dopavision, he worked at Novartis Pharmaceuticals for 12 years, most recently as Global Program Manager in the Ophthalmology Development Unit (2015-2022), Global Brand Manager, Retina, New Products (2013 -2015) and Head of Portfolio Management and Global Decision Support (2010-2013). Prior to Novartis, Mark Wuttke was co-founder and director at Asten BioPharma Advisors, LLC in New York (2007-2009). During his career, he notably held the positions of Associate Research Analyst US Major Pharmaceuticals at Credit Suisse, Associate Management Consulting at Booz & Co and Marketing & Sales Manager at Cognia Corporation. Mark Wuttke holds a Ph.D. in biology from Temple University, Philadelphia, PA.
“We are delighted to welcome Mark as our new CEO,” said Stefan Zundel, co-founder of Dopavision. “We have only just transitioned to a clinical-stage company and Mark’s expertise and leadership skills will be invaluable in advancing our core MyopiaX program into successful digital therapy. Mark is a great candidate, great personality, and our whole team looks forward to working with him.”
“I am delighted to join Dopavision at this crucial stage of development,” added Mark Wuttke, CEO of Dopavision. “MyopiaX is designed to be the first digital treatment for childhood myopia and our goal is to bring this transformative treatment to patients as soon as possible. Childhood myopia is a growing public health problem and our approach aims to combine play with a therapeutic effect, which makes it a very attractive medical solution for children and adolescents.”
MyopiaX® is based on patented light-based technology that stimulates specific light-sensitive cells in the retina, which in turn modulate retinal dopamine, a key neurotransmitter involved in eye growth. The Company has demonstrated proof of the mechanism in preclinical models and exploratory human studies and is currently sponsoring a clinical trial in several European countries. MyopiaX® has the potential to become the first digital therapy to control childhood myopia. It is designed to achieve medical effect while kids are playing exciting games or using educational digital content. MyopiaX® works on standard digital devices and is easy for kids to use, requiring minimal parental supervision.
Dopavision is a pioneer in the development of digital therapeutics. Its flagship product MyopiaX® is currently undergoing clinical trials in Germany, Portugal, Spain and Ireland. It is designed as a breakthrough treatment for childhood myopia that can be seamlessly and invisibly integrated into smartphone use.
Nearsightedness, or nearsightedness, is a visual condition that affects an average of one in three people worldwide, a share that has grown rapidly over the past two decades and accelerated further during the COVID-19 pandemic. High myopia in children poses a significant risk of causing visual impairment and even blindness later in life. Dopavision’s goal is to develop a clinically validated therapy to halt the progression of myopia in children and adolescents.
Founded in 2017 by Hamed Bahmani and Stefan Zundel, Dopavision has so far raised €15 million in venture capital and public grants and is backed by leading international investors such as Seventure Partners, Novartis Pharma and Boehringer Ingelheim Venture Fund. Dopavision is supported by the German government through the “Industrie-in-Klinik” program of the German Federal Ministry of Education and Research BMBF (Aktionsfeld “Gesundheitswirtschaft im Rahmenprogramm Gesundheitsforschung”, Förderkennzeichen/contract number 13GW0256).
For more information, please contact:
Chief executive officer
Dr. Ludger Wess / Ines-Regina Buth
Such. +49 40 88 16 59 64 /
Such. +49 30 23 63 27 68